Evoke Pharma Inc (EVOK)
4.366
+0.11
(+2.48%)
USD |
NASDAQ |
Nov 14, 16:00
4.56
+0.19
(+4.45%)
After-Hours: 20:00
Evoke Pharma Research and Development Expense (Quarterly): 0.0117M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.0117M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.0046M |
| December 31, 2023 | 0.0226M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.0924M |
| March 31, 2023 | 0.067M |
| December 31, 2022 | 0.0272M |
| September 30, 2022 | 0.0404M |
| June 30, 2022 | 0.1915M |
| March 31, 2022 | 0.0417M |
| December 31, 2021 | 0.0357M |
| September 30, 2021 | 0.0817M |
| June 30, 2021 | 0.1952M |
| March 31, 2021 | 0.2778M |
| December 31, 2020 | 0.1038M |
| September 30, 2020 | 0.205M |
| June 30, 2020 | 5.782M |
| March 31, 2020 | 0.4639M |
| December 31, 2019 | 0.6415M |
| September 30, 2019 | 0.8224M |
| June 30, 2019 | 1.206M |
| March 31, 2019 | 0.7469M |
| December 31, 2018 | 0.6954M |
| September 30, 2018 | 0.6255M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.389M |
| March 31, 2018 | 1.385M |
| December 31, 2017 | 1.632M |
| September 30, 2017 | 2.718M |
| June 30, 2017 | 2.018M |
| March 31, 2017 | 0.7707M |
| December 31, 2016 | 1.502M |
| September 30, 2016 | 1.339M |
| June 30, 2016 | 2.095M |
| March 31, 2016 | 2.015M |
| December 31, 2015 | 1.708M |
| September 30, 2015 | 1.838M |
| June 30, 2015 | 2.188M |
| March 31, 2015 | 2.42M |
| December 31, 2014 | 2.176M |
| September 30, 2014 | 3.088M |
| June 30, 2014 | 2.875M |
| March 31, 2014 | 1.852M |
| December 31, 2013 | 0.6364M |
| September 30, 2013 | 0.0787M |
| June 30, 2013 | 0.1308M |
| March 31, 2013 | 0.111M |
| December 31, 2012 | 0.3183M |
| September 30, 2012 | 0.337M |
| June 30, 2012 | 0.213M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2023
5.782M
Maximum
Jun 2020
0.4143M
Average
0.0743M
Median
Research and Development Expense (Quarterly) Benchmarks
| Repligen Corp | 10.58M |
| Eli Lilly and Co | 2.734B |
| MEI Pharma Inc | 3.944M |
| Revance Therapeutics Inc | 11.38M |
| NovaBay Pharmaceuticals Inc | 0.004M |